<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230821059213N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-06</date_registration>
      <primary_sponsor>Vice chancellor for research, Shahid Beheshti University of Medical sciences- School of Nutrition</primary_sponsor>
      <public_title>The effect of time-restricted feeding (TRF) combined with a Lacto-Ovo-Vegetarian (LOV) diet on controlling of non-alcoholic fatty liver disease</public_title>
      <acronym></acronym>
      <scientific_title>The effect of time-restricted feeding (TRF) combined with a Lacto-Ovo-Vegetarian (LOV) diet on anthropometric indices, body composition, hepatic parameters, glucose homeostasis, lipid profile and inflammatory biomarkers in overweight and obese patients with non-alcoholic fatty liver disease: a Randomized Control Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72231</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The first step is to create a random sequence number. For this purpose, we will use a random number generator on Stat trek (https://stattrek.com/statistics/random-number-generator.aspx) for 50 numbers ranging from 1 to 2 (for example 2 1 1 2 1 2 1 1 2 2 2 1 1 2 2 1 2 2...).Then, we will specify the numbers to the groups, for example, 1 will be assigned to the intervention group, and the numbers 2 to the control group. Each number will represent a group according to the defined numbers. With this method, we will have a specific sequence of 50 codes of 1, 2, which shows the first to 50th people who are going to be entered into the study in each group. We write the codes on a piece of paper and put them in an envelope to use during sampling. Thus, after reviewing the inclusion criteria and if the participants desire, we will enter each person included in the study according to our predetermined list.</study_design>
      <phase>3</phase>
      <hc_freetext>Non-alcoholic fatty liver disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Receiving a 3-month diet plan based on the personal  energy requirement calculated according to the Mifflin formula and in the form of a combination of the 16:8 time-restricted feeding method, in which food intake is limited to an 8-hour period, followed by a 16-hour fasting period (for example, 8 pm to 12 noon) According to the fact that during the 16-hour fasting, it is free to drink non-caloric substances such as water, coffee and tea; And the lacto-ovo-vegetarian diet, in which the consumption of red meat, poultry, fish, and other products containing this group of foods is not allowed in this diet. Intervention 2: Control group: Receiving nutritional recommendations for disease control such as: Avoiding excessive consumption of sugar, jam, honey, syrup, soft drinks and other foods that contain sugar and alcoholic beverages. Avoiding high consumption of high-fat foods, oil and fried foods. And also Eating a variety of vegetables with meals.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahshad Shafiee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nutrition Sciences &amp; Food Technology., Hafezi Ave., Farahzadi Blvd., Qods town</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981619573</zip>
        <telephone>+98 21 2235 7483</telephone>
        <email>mahshadshafiee97@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atousa Saeidpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nutrition Sciences &amp; Food Technology., Hafezi Ave., Farahzadi Blvd., Qods town</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1981619573</zip>
        <telephone>+98 21 2235 7483</telephone>
        <email>atoosa.saidpour@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Body mass index higher than 24.9 (BMI≥25)
Having evidence of steatohepatitis and non-alcoholic fatty liver based on the confirmation of the attending physician and the patient's laboratory and ultrasound results
Not having a history of alcohol consumption or alcohol consumption less than 10 grams per day in women and less than 20 grams per day in men
Willingness to participate in the study and ability to complete the study process</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having other chronic and acute liver diseases and disorders (hepatitis B, C, etc.), biliary disease, kidney diseases, endocrine disorders, confirmed autoimmune diseases, cancer and hereditary disorders affecting the liver (iron and copper storage disease)
Having uncontrolled cardiovascular diseases, chronic inflammatory disease, diabetes and celiac disease
Alcoholism or drug abuse
Pregnancy or Lactation in women
Consumption of hepatotoxic drugs such as phenytoin, amoxifen and lithium
Consumption of fiber, omega-3 and antioxidant supplements during the last 3 months
Consumption of weight loss drugs or supplements
Following special weight loss diets during the last 3 months
Losing more than 10% of body weight during the last 6 months
Failure to accept study conditions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K76.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fatty (change of) liver, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Receiving a 3-month diet plan based on the personal  energy requirement calculated according to the Mifflin formula and in the form of a combination of the 16:8 time-restricted feeding method, in which food intake is limited to an 8-hour period, followed by a 16-hour fasting period (for example, 8 pm to 12 noon) According to the fact that during the 16-hour fasting, it is free to drink non-caloric substances such as water, coffee and tea; And the lacto-ovo-vegetarian diet, in which the consumption of red meat, poultry, fish, and other products containing this group of foods is not allowed in this diet.</i_keyword>
      <i_keyword>Control group: Receiving nutritional recommendations for disease control such as: Avoiding excessive consumption of sugar, jam, honey, syrup, soft drinks and other foods that contain sugar and alcoholic beverages. Avoiding high consumption of high-fat foods, oil and fried foods. And also Eating a variety of vegetables with meals.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Scale.</prim_outcome>
      <prim_outcome>Fibrosis index (FIB-4). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body Mass Index (BMI). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>Fat Mass. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Bio Impedance Analyzer.</sec_outcome>
      <sec_outcome>Fat Free Mass. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Bio Impedance Analyzer.</sec_outcome>
      <sec_outcome>Fatty Liver Index (FLI). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>BARD score. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>AST to Platelet Ratio Index (APRI). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>Serum lipid profile (total cholesterol, triglyceride, HDL-C, LDL-C). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Blood sample.</sec_outcome>
      <sec_outcome>Liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Blood sample.</sec_outcome>
      <sec_outcome>Serum Insulin and Fasting Blood Sugar (FBS). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Blood sample.</sec_outcome>
      <sec_outcome>Insulin sensitivity index (QUICKI) and Insulin resistance index (HOMA-IR). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>Tumor necrosis factor alpha (TNF-α). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Blood sample.</sec_outcome>
      <sec_outcome>High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Blood sample.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Shahid Beheshti University of Medical sciences- School of Nutrition</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-15</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>School of Nutrition Sciences &amp; Food Technology., Hafezi Ave., Farahzadi Blvd., Qods town Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
